Somatostatin receptor (SSR)-based theranostics: neuroendocrine tumours and beyond
Irene Virgolini, Innsbruck / Austria
1. To become familiar with SSR-based radiopharmaceuticals.
2. To become familiar with clinical indications for SSR-based peptide receptor radionuclide therapy.
3. To understand the role of hybrid imaging in therapy planning and response assessment.